Form D · Biotechnology
ENGEN BIO, LLC
Redwood City, CA · CIK 0001800174
Offering snapshot reported Jan 17, 2020 · SEC filing
- Reported sold
- $632K Offering amount: $632K
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Jan 3, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 17, 2020 | Initial | $632,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $15K
- Finders' fees
- $0
- Form D file number
- 021-358412
In addition to the sales commissions, the Company will issue 8,000 units to the broker/dealer.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| TRANCEKA CAPITAL, LLC | 118028 |
Source: Form D, filed Jan 17, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Alfenito | Director, Executive |
| Adam M Guttmann | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
61 Avondale Ave
Redwood City, CA, 94062
Redwood City, CA, 94062